Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mtic SCHEMBL22757309 | 1.00 | GDA (0.36) | GDALMNATSHRPAX8KDM4E | |
| SCHEMBL28386283 | 0.75 | GDA (0.37) | GDALMNATSHRPAX8KDM4E | |
| SCHEMBL15131350 | 0.75 | GDA (0.39) | GDALMNATSHRPAX8KDM4E | |
| SCHEMBL18737907 | 0.74 | PAX8 (0.38) | GDALMNATSHRPAX8KDM4E | |
| SCHEMBL13348562 | 0.74 | GDA (0.41) | GDALMNATSHRPAX8KDM4E | |
| SCHEMBL14034284 | 0.74 | GDA (0.41) | GDALMNATSHRPAX8KDM4E | |
| SCHEMBL12259351 | 0.73 | MAPK1 (0.40) | GDAPAX8SMN1; SMN2 | |
| SCHEMBL28543470 | 0.73 | GDA (0.40) | GDAKDM4EALDH1A1SMN1; SMN2GAA | |
| SCHEMBL4210787 | 0.71 | GDA (0.39) | GDALMNATSHRPAX8KDM4E | |
| SCHEMBL1059195 | 0.71 | GDA (0.39) | GDALMNATSHRPAX8KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258119-B2 | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | Kasina Laila Innova Pharmaceuticals (IN) | 2012-09-04 | — | — | US | disclosed |
| US-8258119-B2 | Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers | Kasina Laila Innova Pharmaceuticals (IN) | 2012-09-04 | — | — | US | disclosed |
| US-8143237-B2 | Anti-cancer drugs, and uses relating for malignant melanoma and other cancers | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143237-B2 | Anti-cancer drugs, and uses relating for malignant melanoma and other cancers | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITED (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100272678-A1 | ANTI-CANCER DRUGS, AND USES RELATING FOR MALIGNANT MELANOMA AND OTHER CANCERS | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITE (IN) | 2010-10-28 | — | — | US | disclosed |
| US-20100272678-A1 | ANTI-CANCER DRUGS, AND USES RELATING FOR MALIGNANT MELANOMA AND OTHER CANCERS | KASINA LAILA INNOVA PHARMACEUTICALS PRIVATE LIMITE (IN) | 2010-10-28 | — | — | US | disclosed |
| US-20100068178-A1 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | LAILA NUTRACEUTICALS (IN) | 2010-03-18 | — | — | US | disclosed |
| US-20100068178-A1 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | LAILA NUTRACEUTICALS (IN) | 2010-03-18 | — | — | US | disclosed |
| US-7572798-B2 | Prevent Dna damage; antitumor, anticancer agents; blocking epidermal growth factor receptor | MCGILL UNIVERSITY (CA) | 2009-08-11 | — | — | US | disclosed |
| US-7572798-B2 | Prevent Dna damage; antitumor, anticancer agents; blocking epidermal growth factor receptor | MCGILL UNIVERSITY (CA) | 2009-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272678-A1 | ANTI-CANCER DRUGS, AND USES RELATING FOR MALIGNANT MELANOMA AND OTHER CANCERS | BRAF, TPD52L2, SALL4 | GDA 4395/4885LMNA 3063/4885TSHR 74/4885 |
| US-20100068178-A1 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS | BRAF, NRAS, TP53 | GDA 1130/4885LMNA 1600/4885TSHR 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.